Advertisement

Eosinophile Dermatosen und Syndrome

  • Constantin E. Orfanos
  • Claus Garbe

Zusammenfassung

Der eosinophile Granulozyt hat seinen Ursprung in Stammzellen des Knochenmarks und ist an einer Vielzahl pathogenetischer Reaktionen im Körper beteiligt. Im Verlauf der Ausschüttung eosinophiler Granula kommt es zur Freisetzung von Sauerstoffmetaboliten, basischen Proteinen und Enzymen (Tabelle 23.1). Außerdem interagieren die Proteinprodukte des eosinophilen Granulozyten mit den Effektormechanismen anderer Entzündungszellen, z. B. Makrophagen, Mastzellen und Thrombozyten. Mastzellen, Basophile, Komplement C5a, Fibrinbestandteile, Antigenantikörperkomplexe u. v.a. sind in der Lage, gezielt Eosinophile zu attrahieren.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aberer W, Konrad K, Wolff K (1988) Wells’ syndrome is a distinctive disease entity and not a histological diagnosis. J Am Acad Dermatol 18: 105–114PubMedCrossRefGoogle Scholar
  2. Altman LC, Hill JS, Harfield WM, Mullarky KF (1981) Effect of corticosteroids on eosinophilic chemotaxis and adherence. J Clin Invest 67: 28–36PubMedCrossRefGoogle Scholar
  3. Anderson CR (1975) Dapsone in granuloma faciale (letter). Lancet 1: 642PubMedCrossRefGoogle Scholar
  4. Arzneimittelkommission der Deutschen Ärzteschaft (1989) Einschränkung der Anwendungsgebiete LTryptophan-haltiger Fertigarzneimittel. Dtsch Ärztebl 86: 2692Google Scholar
  5. Basran GS, Page CP, Paul W, Morley J (1983) Cromoglycate (DSCG) inhibits responses to platelet activating factor in man: an alternative mode of action for DSCG in asthma. Eur J Pharmacol 86: 143–144CrossRefGoogle Scholar
  6. Berbis P, Jancovici E, Lebreuil G et al. (1989) Eosinophilic pustular folliculitis (Ofuji’s diseases: efficacy of isotretinoin. Dermatologica 179: 214–216PubMedCrossRefGoogle Scholar
  7. Bergfeld WF et al. (1976) Granuloma faciale treated by dermabrasio. Cleve Clin Q 37: 215Google Scholar
  8. Britt WJ, Duray PH, Dahl MN et al. (1980) Diffuse fasciitis with eosinophilia: a steroid responsive variant of scleroderma. J Pediatr 97: 432–434PubMedCrossRefGoogle Scholar
  9. Buchness MR, Lim HW, Hatcher VA et al. (1988) Eosinophilic pustular folliculitis in the acquired immune deficiency syndrome: treatment with ultraviolet B phototherapy. N Engl J Med 318: 1183–1186PubMedCrossRefGoogle Scholar
  10. CDC (1990) Eosinophilia-myalgia-syndrome — New Mexico. MMWR 38: 765–767Google Scholar
  11. Chun Si JHG (1992) Kimura’s disease and angiolymphoid hyperplasie with eosinophilia. Clinical and pathological differences. J Am Acad Dermatol 27: 954–958PubMedCrossRefGoogle Scholar
  12. Chusid MJ, Dale DG, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of 14 cases with review of literature. Medicine 54: 1–27PubMedCrossRefGoogle Scholar
  13. Clauw DJ, Nashel DJ, Umhau A et al. (1990) Tryptophan associated eosinophilic connective tissue disease. JAMA 263: 1502–1506PubMedCrossRefGoogle Scholar
  14. Fauci AS, Harley J, Roberts W et al. (1982) The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic and therapeutic considerations. Ann Intern Med 97: 78–92PubMedGoogle Scholar
  15. Freundlich B, Werth VP, Rok AW et al. (1990) L-Tryptophan injection associated with eosinophilic fasciitis but not progressive systemic sclerosis. Ann Intern Med 2: 758–762Google Scholar
  16. Giard F, Marcoux D, McCuaig C et al. (1991) Eosinophilic pustular folliculitis (Ofuji disease) in childhood: a review of four cases. Pediatr Dermatol 8: 189–193PubMedCrossRefGoogle Scholar
  17. Gizycki-Nienhaus B von, Meurer M, Krieg T et al. (1991) Eosinophilie-Myalgie-Syndrom und L-Tryptophaneinnahme. Hautarzt 42: 179–182Google Scholar
  18. Guill MA, Aton JK (1982) Facial granuloma responsive to dapsone therapy. Arch Dermatol 118: 332PubMedCrossRefGoogle Scholar
  19. Hardy WR, Anderson RE (1968) The hypereosinophilic syndromes. Ann Intern Med 68: 1220–1229PubMedGoogle Scholar
  20. Henocq E, Vargaftig BB (1988) Skin eosinophilia in atopic patients. J Allergy Clin Immunol 81: 691–695PubMedCrossRefGoogle Scholar
  21. Herson S, Brechignac S, Piette JC (1990) Capillary microscopy during eosinophilic fasciitis in 15 patients: distinction from systemic scleroderma. Am J Med 88: 598–600PubMedCrossRefGoogle Scholar
  22. Hertzman PA, Blevins WL, Mayer J et al. (1990) Association of the eosinophilia-myalgia-syndrome with the ingestion of tryptophan. N Engl J Med 322: 869–873PubMedCrossRefGoogle Scholar
  23. Hintner H, Tappeiner G, Egg D, Wolff K (1981) Fasziitis mit Eosinophilie. Das Shulman-Syndrom. Hautarzt 32: 75–79PubMedGoogle Scholar
  24. Hoffmann A, Kuhn A, Albig SJ et al. (1993) Eosinophilie-Myalgie-Syndrom nach Einnahme von L-Tryptophan. Zwei Fallberichte. Z Hautkr 68: 783–788Google Scholar
  25. Ishibashi A, Mishiyama Y, Miyata C et al. (1974) Eosinophilic pustular folliculitis ( Ofuji ). Dermatologica 149: 240–247PubMedCrossRefGoogle Scholar
  26. Jacyk WK (1981) Facial granuloma in a patient treated with clofazimine Arch Dermatol 117: 597–598Google Scholar
  27. Jameson MD, Segraves SD (1988) Idiopathic hypereosinophilic syndrome. Postgrad Med 84: 93–96PubMedGoogle Scholar
  28. Kazmierowski JA, Chusid MJ, Parillo JE et al. (1978) Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol 114: 531–535PubMedCrossRefGoogle Scholar
  29. Kent LT, Cramer SF, Moskowitz RW (1981) Eosinophilic fasciitis. Clinical, laboratory and microscopic considerations. Arthritis Rheum 24: 677–683PubMedCrossRefGoogle Scholar
  30. Kroegel C, Matthys H (1992) Mit dem eosinophilen Granulozyten assoziierte Erkrankungen. Neue pathogenetische und therapeutische Aspekte. Arzneimitteltherapie 10: 140–151Google Scholar
  31. Kuo T, Shih LY, Kola AH (1988) Kimura’s disease. Am J Surg Path 12: 843–854PubMedCrossRefGoogle Scholar
  32. Leprevost C, Capron M, De Vos C, Tomassini M, Capron A (1988) Inhibition of eosinophil chemotaxis by a new antiallergic compound (cetirizine),Int Arch Allergy Clin Immunol 87: 9–13CrossRefGoogle Scholar
  33. Liesveld JL, Abboud CN (1991) State of the art; the hypereosinophilic syndromes. Blood Rev 5: 29–37PubMedCrossRefGoogle Scholar
  34. Lindscheid KR, Zabel M (1988) Hypereosinophiliesyndrom mit kutanen Manifestationen, „BurningHand“-Syndrom und Immunglobulinerhöhungen. Behandlung mit einer Kombination von DADPS mit Dinatriumcromoglykat. Z Hautkr 63: 338–343PubMedGoogle Scholar
  35. Loffin EB (1983) Cimetidine and eosinophilic fasciitis. Ann Intern Med 97: 111–112Google Scholar
  36. Malanin G, Helander I (1989) Eosinophilic pustular folliculitis (Ofuji’s disease): response to dapsone but not to isotretinoin therapy. J Am Acad Dermatol 20: 1121PubMedCrossRefGoogle Scholar
  37. Marcoux C. Bourlond A, Decroix J (1991) Hyperplasie angiolymphoide avec éosinophilie (Hale). Remission sous acitretine. Ann Dermatol Venereol 118: 217–221PubMedGoogle Scholar
  38. Martin RW, Duffy J, Engel AG et al. (1990) The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion: clinical features in 20 patients and aspects of pathophysiology. Ann Intern Med 113: 124–134PubMedGoogle Scholar
  39. Mensing H, Schmidt K-U (1985) Diffuse fasciitis with eosinophilia associated with morphoea and lichen sclerosus et atrophicans. Acta Derm Venereol 65: 80–83PubMedGoogle Scholar
  40. Mensing H, Schallreuter KU, Senff H, Steinkraus V (1992) Das Eosinophilie-Myalgie-Syndrom. Klinik und Verlauf bei 10 Patienten. Hautarzt 43: 436–440PubMedGoogle Scholar
  41. Michel L, De Vos C, Rihoux JP, Burtin C, Benveniste J, Dubertret L (1988) Inhibitory effect of oral cetirizinc on in vivo antigen-induced histamine and PAFacether release and eosinophil recruitment in human skin. J Allergy Clin Immunol 82: 101–109PubMedCrossRefGoogle Scholar
  42. Newton JA, Singh AK, Greaves MW et al. (1990) Aqua-genic pruritus associated with the idiopathic hypereosinophilic syndrome. Br J Dermatol 122: 103–106PubMedCrossRefGoogle Scholar
  43. Nir MA, Westfried M (1981) Hypereosinophilic dermatitis. A distinct manifestation of the hypereosinophilic syndrome with response to dapsone. Dermatologica 161: 445–450Google Scholar
  44. Oppolzer G, Duschet P, Schwarz T et al. (1988) Die hypereosinophile Dermatitis (Nir-Westfried). Eine Variante im Spektrum des Hypereosinophilie-Syndroms. Z Hautkr 63: 123–125PubMedGoogle Scholar
  45. Orfanos CE, Sterry W (1978) Sterile eosinophile Pustulose. Dermatologica 157: 193–205PubMedCrossRefGoogle Scholar
  46. Porneuf M, Guillot B, Barneon G, Guilhou JJ (1993) Eosinophilic pustular folliculitis responding to UVBtherapy. J Am Acad Dermatol 29: 259–260PubMedCrossRefGoogle Scholar
  47. Reinauer S, Plewig G (1991) Das Eosinophilie-Myalgie-Syndrom. Hautarzt 42: 137–139PubMedGoogle Scholar
  48. Senff H, Köllner A, Engelmann L et al. (1990) L-Tryptophan induziertes Eosinophilie-Myalgie-Syndrom unter dem Bild einer diffusen eosinophilen Fasziitis mit Eosinophilie. Hautarzt 41: 578–582PubMedGoogle Scholar
  49. Silver RM, Heyes MP, Maize JC et al. (1990) Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med 322: 874–881PubMedCrossRefGoogle Scholar
  50. Solomon G, Barland P, Rifkin H (1982) Eosinophilic fasciitis responsive to cimetidine. Ann Intern Med 97: 547–549PubMedGoogle Scholar
  51. Souillet G, Rousset F, de Vries JE (1989) Alpha-Interferon treatment of a patient with hyper IgE-syndrome. Lancet 1: 1384PubMedCrossRefGoogle Scholar
  52. Spira I, Simon M, Keller J (1986) Sterile eosinophilic pustulose. Hautarzt 37: 222–225PubMedGoogle Scholar
  53. Spry CJF (1982) The hypereosinophilic syndrome: Clinical features, laboratory findings and treatment. Allergy 37: 539–551PubMedCrossRefGoogle Scholar
  54. Spry CJF, Davies J, Tai PC et al. (1983) Clinical features of 15 patients with the hypereosinophilic syndrome. Quart J Med 52: 1PubMedGoogle Scholar
  55. Szeimies RM, Meurer M (1993) Tryptophan-assoziiertes Eosinophilie-Myalgie-Syndrom. Klinische Verlaufsbeobachtung bei acht Patienten. Dtsch Med Wochenschr 118: 213–220PubMedCrossRefGoogle Scholar
  56. Tale’) A, Bassan-Andrien L, Maleville J (1992) Eosinophilic pustulosis of the scalp in childhood. J Am Acad Dermatol 27: 55–60CrossRefGoogle Scholar
  57. Takematsu H, Nakamura K, Igarashi M, Tagami H (1985) Eosinophilic pustular folliculitis. Report of two cases with a review of the Japanese literature. Arch Dermatol 121: 917–920PubMedCrossRefGoogle Scholar
  58. Varga J, Vitto J, Jimenez SA (1992) The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med 116: 140–147PubMedGoogle Scholar
  59. Varga J, Jimenez SA, Vitto J (1993) L-Tryptophan and the eosinophilic-myalgia syndrome: current understanding of the etiology and pathogenesis. J Invest Dermatol 100: 97S - 105SPubMedCrossRefGoogle Scholar
  60. Wells GC, Smith NP (1979) Eosinophilic cellulitis. Br J Dermatol 100: 101–109PubMedCrossRefGoogle Scholar
  61. Wemmer U, Thiele B, Steigleder GK (1988) Hypereosinophilie-Syndrom ( HES) - erfolgreiche PUVA-Therapie. Hautarzt 39: 42–44PubMedGoogle Scholar
  62. Wells GC, Whimster IW (1969) Subcutaneous angiolymphoid hyperplasia with eosinophilia. Br J Dermatol 81: 1–15PubMedCrossRefGoogle Scholar
  63. Whittaker SJ, Jones RR, Spry CJ (1988) Lymphomatoid papulosis and its relationship to „idiopathic“ hypereosinophilic syndrome. J Am Acad Dermatol 18: 339–344PubMedCrossRefGoogle Scholar
  64. Wood ML, Slater DN (1984) Cutaneous manifestations of the hypereosinophilic syndrome treated with sodium cromoglycate. Clin Exp Dermatol 9: 139–142PubMedCrossRefGoogle Scholar
  65. Zillikens D, Bammel A, Lurz C et al. (1991) Eosinophilie-Myalgie-Syndrom nach Einnahme von L-Tryptophan. Hautarzt 42: 154–157PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Constantin E. Orfanos
    • 1
  • Claus Garbe
    • 1
  1. 1.Universitäts-Hautklinik und PoliklinikKlinikum Benjamin Franklin der Freien Universität BerlinBerlinDeutschland

Personalised recommendations